Alcon, ophthalmology division of Swiss pharmaceutical company Novartis, has received FDA approval for Simbrinza, the company's fixed-dose combination glaucoma therapy, according to a report by thepharmaletter.
Simbrinza, a 1.0 percent brinzolamide and 0.2 percent brimonidine tartrate suspension, has proven to decrease intraocular pressure by 21 to 35 percent.
Alcon's glaucoma therapy is currently the only fixed-dose combination without a beta blocker to be offered in the U.S.
More Articles on Ophthalmology:
Twin Falls Vision Clinic Expands, Recruits Dr. Kyle Klingler
3 Statistics on Cataract Surgery Procedure Times in ASCs
Bausch + Lomb, Leica Microsystems Make Global Distributing Agreement
Simbrinza, a 1.0 percent brinzolamide and 0.2 percent brimonidine tartrate suspension, has proven to decrease intraocular pressure by 21 to 35 percent.
Alcon's glaucoma therapy is currently the only fixed-dose combination without a beta blocker to be offered in the U.S.
More Articles on Ophthalmology:
Twin Falls Vision Clinic Expands, Recruits Dr. Kyle Klingler
3 Statistics on Cataract Surgery Procedure Times in ASCs
Bausch + Lomb, Leica Microsystems Make Global Distributing Agreement